4,901 trials
Neoplasms, Advanced Solid
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 0 participants
Healthy Subjects
Primary: AUC (0-t) of Plasma Metformin — 6164; 9014; 18709; 16989 ng*h/mL — p=<0.001
Hepatitis C, Chronic
Primary: Efficacy: VR (Virologic Response) of >=2 log10 Reduction in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) From Baseline at Any Time up to Day 14 (naïve Patients)…
Chronic Hepatitis C
Primary: Maximum Observed Plasma Concentration (Cmax) of Ethinyl Estradiol — 118.53; 134.70 picogram per millilitre (pg/mL)
Urinary Tract Infection
Primary: Rate of UTI While Colonized With E. Coli 83972. — 8.5 UTIs per 1000 patient-days
Tobacco Use Disorder
Primary: 7-day Point Prevalence Abstinence — 4; 1 participants
Intracerebral Hemorrhage · Hypertension · Stroke
Primary: Particpants Who Achieve and Maintain the Systolic Blood Pressure Goals for Each Treatment Tier. — 18; 20; 22; 7 participants — p=< 0.01
Invasive Aspergillosis
Primary: Number of Subjects With Adverse Events — 1; 1; 1; 1 participants
Low Risk (0-10% Chance) of Developing Cardiovascular Disease Within 10 Years Based on Risk Factors · Moderate Risk (10-20% Chance) of Developing Cardiovascular (Heart) Disease Within 10 Years Based on Risk Factors
Primary: LDL-C in All ICAT Group Participants Versus Non-ICAT Group Participants — 126.2; 126.0; 103.2; 107.7 mg/dL
Age-Related Macular Degeneration
Primary: Number of Subjects With a Serious Adverse Event That, in the Opinion of the Investigator, is Related to the Study Drug, Part 1 — 0; 0; 0; 0 participants
Schizophrenia
Primary: Unbound Brexpiprazole Area Under the Concentration Time Curve (AUC) Calculated to the Last Observable Concentration at Time t (AUCt,u) — 5.95; 4.87; 5.41; 4.28…
Healthy
Primary: Empa: Area Under the Curve 0 to Infinity (AUC0-∞) — 2560; 2530; 986; 968 nmol*h/L
Neoplasms
Primary: Maximum Tolerated Dose (MTD) — 10.0 mg/kg
Multiple Myeloma
Primary: Number of Participants Reporting One or More Treatment-Emergent Adverse Events and Serious Adverse Events — 3; 3; 2; 3 participants
Mild and Moderate Renal Impairment
Primary: Time to Reach Maximum Peak Plasma Concentration (Tmax) After Single Dose (Day 1), and After Multiple Dose Administration (Day 5) — 1; 0.5; 0.5; 0.5 hr